title: Bortezomib Based Chemotherapy for Light Chain Deposition Disease.
abstract: Light chain deposition disease (LCDD) is a rare systemic disorder in which monoclonal light chains are abnormally secreted due to clonal proliferation of plasma cells and get deposited in various organs; the kidneys being the common one to be affected leading to renal failure. Advocated therapeutic options include chemotherapy with alkylating agents and steroids, High-Dose Melphalan (HDM) with Autologous Stem Cell Transplantation. Recently, Bortezomib has proven to be a novel therapeutic option in these patients when combined with dexamethasone. Here, we report a patient who presented with acute renal failure, was diagnosed to have LCDD and treated with bortezomib and dexamethasone.
authors.affiliation: Assistant Professor, Department of Medical Oncology.
authors.forename: Vignesh
authors.initials: V
authors.lastname: Kandakumar
authors.affiliation: Final Year MBBS Student.
authors.forename: Vishnu
authors.initials: V
authors.lastname: Nagalapuram
authors.affiliation: Professor, Department of General Medicine, PSG Institute of Medical Sciences & Research, Coimbatore, Tamil Nadu.
authors.forename: Sujaya
authors.initials: S
authors.lastname: Menon
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000069286:Bortezomib / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D009101:Multiple Myeloma / Q000188:drug therapy*
chemical_list: D000970:Antineoplastic Agents; D000069286:Bortezomib